Protagonist Therapeutics, a spin-out company from IMB, has begun clinical trials with a novel drug candidate being investigated as a potential 'oral targeted therapy' for inflammatory bowel diseases.
Researchers from the Institute for Molecular Bioscience (IMB) have made advances in understanding the cellular processes that occur during wound healing, skin cancer, and inflammatory skin conditions such as psoriasis.
University of Queensland PhD student Zoe Schofield is investigating the link between gut bacteria, diet and the human immune system to reduce inflammatory injury.
University of Queensland researchers have discovered a new signalling pathway that controls cell adhesion, an important process that is disrupted in diseases such as skin cancer and inflammation.
Protagonist Therapeutics, a spin-out company from The University of Queensland’s Institute for Molecular Bioscience (IMB), has raised $40 million to begin clinical trials of an oral drug for Inflammatory Bowel Disease.
UQ researchers are developing a new asthma treatment that targets the underlying cause of asthma, rather than just the symptoms. UQ Institute of Molecular Bioscience’s Associate Professor Mark Smythe said the research team was developing a new drug designed to offer patients a safer and more effective treatment.
Scientists in Brisbane and Ireland have developed a small molecule that blocks a key driver of inflammatory diseases – a finding that could inspire new treatments for arthritis, multiple sclerosis and a family of rare autoinflammatory diseases.
Researchers from The University of Queensland’s Institute for Molecular Bioscience have uncovered a secret of an immune cell on the frontline that could assist with developing new treatments for inflammatory diseases.
University of Queensland researchers have discovered how an important pair of molecules—found within the cells of our immune system—team up to help ‘switch off’ inflammation in the body.
